Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline salt and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline salt.
1. A method of treating a central nervous system disorder in a patient in need thereof, the method comprising orally administering between 75 mg and 300 mg xanomeline salt and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline salt.
2. The method of claim 1 , wherein the central nervous system disorder is schizophrenia.
3. The method of claim 1 , wherein the central nervous system disorder is Alzheimer's disease.
4. The method of claim 1 , wherein the central nervous system disorder is Huntington's disease.
5. The method of claim 1 , wherein the central nervous system disorder is Parkinson's disease.
6. The method of claim 1 , wherein the central nervous system disorder is Lewy Body dementia.
7. The method of claim 1 , wherein 225 mg of xanomeline salt and between 20 mg and 60 mg of trospium chloride are administered to the patient during the 24-hour period.
8. The method of claim 1 , wherein the xanomeline salt and the trospium chloride are in the same dosage vehicle.
9. The method of claim 1 , wherein the xanomeline salt and the trospium chloride are in different dosage vehicles.
10. The method of claim 1 , wherein xanomeline salt is administered to the patient three times during the 24-hour period.
11. The method of claim 1 , wherein trospium chloride is administered to the patient two times during the 24-hour period.
12. The method of claim 1 , wherein between 20 mg and 60 mg of trospium chloride is administered to the patient during the 24-hour period.
13. The method of claim 1 , wherein between 60 and 200 mg trospium chloride is administered to the patient during the 24-hour period.
14. The method of claim 1 , wherein between 75 mg and 225 mg xanomeline salt and between 20 mg and 60 mg trospium chloride are administered to the patient during the 24-hour period.
15. The method of claim 1 , wherein 300 mg xanomeline salt and between 60 mg and 200 mg trospium chloride are administered to the patient during a 24-hour period.
16. The method of claim 1 , wherein the xanomeline salt is the salt of tartaric acid.